UniProtKB/Swiss-Prot P10632 : Variant p.His411Leu
Cytochrome P450 2C8
Gene: CYP2C8
Feedback ?
Variant information
Variant position:
411
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LB/B
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Histidine (H) to Leucine (L) at position 411 (H411L, p.His411Leu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from medium size and polar (H) to medium size and hydrophobic (L)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Polymorphism:
Several alleles are found in the human population, contributing to interindividual variations in the therapeutic efficacy and toxicity of a myriad of drugs such as paclitaxel or amodiaquine. The allele shown here is CYP2C8*1 (PubMed:26427316 ). CYP2C8 genetic variations are associated with altered drug metabolism and adverse drug effects including acute rhabdomyolysis after cerivastatin use [MIM:618018 ].
Additional information on the polymorphism described.
Sequence information
Variant position:
411
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
490
The length of the canonical sequence.
Location on the sequence:
LTSVLHDDKEFPNPNIFDPG
H FLDKNGNFKKSDYFMPFSAG
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Literature citations
Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform.
Zeldin D.C.; DuBois R.N.; Falck J.R.; Capdevila J.H.;
Arch. Biochem. Biophys. 322:76-86(1995)
Cited for: PROTEIN SEQUENCE OF 2-15; NUCLEOTIDE SEQUENCE [MRNA] OF 6-490; FUNCTION; CATALYTIC ACTIVITY; PATHWAY; VARIANT LEU-411;
Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4'-hydroxylase.
Ged C.; Umbenhauer D.R.; Bellew T.M.; Bork R.W.; Srivastava P.K.; Shinriki N.; Lloyd R.S.; Guengerich F.P.;
Biochemistry 27:6929-6940(1988)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 11-490 (ISOFORM 1); VARIANTS ASP-154; LYS-193; ARG-249 AND LEU-411;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.